Situated in Western Europe and with several overseas regions and territories, France is one of the strongest economies and supporters in Europe. With a combined OTC and Pharma market value of US $39 billion, France is certainly a mature market.
The slight growth of the French market is the result of the use of generics. Nevertheless, the combination of a lack of innovative products and a gigantic market value allows a lot of pharmaceutical companies to expand in the country. What’s more, the OTC market in France is increasing more than the Rx sector; people have recently been able to self-select certain OTC products in pharmacies. The average French citizen spends US $110 per year in the 23,100 pharmacies without drugstores for OTC products in the country, which is a pretty high number for Europe. The pharmacy density in France is 2,800 inhabitants per pharmacy.
The OTC share in France amounts to 12%. With an OTC market value of US $4.68 billion in 2012, France is going to be a global player in this sector. Governmental support has allowed France to remain an attractive player in the pharmaceutical sector—and an attractive location for Pharma companies from all over the world.